SCHEMBL4976388

SCHEMBL4976388

Cc1cccc(C(=O)N2CCc3c(ncnc3N3CCN(C4CCC4)CC3)C2)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM2B Q8NHM5 3/20 0.53
ALDH1A1 P00352 2/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HPGD P15428 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
KDM4E B2RXH2 1/20 0.42
KCNK3 O14649 1/20 0.42
KCNK9 Q9NPC2 1/20 0.42
P2RX7 Q99572 2/20 0.41
CDK4 P11802 1/20 0.41
CCND1 P24385 1/20 0.41
L3MBTL3 Q96JM7 1/20 0.41
GRM5 P41594 2/20 0.40
CHRM1 P11229 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4976961 0.89 HTT (0.53) KDM2BALDH1A1HTTSMN1; SMN2HPGD
SCHEMBL4978484 0.89 KDM2B (0.50) KDM2BALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4980177 0.89 KCNK3 (0.49) KDM2BALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL4976699 0.89 KDM2B (0.55) KDM2BALDH1A1LMNAHPGDMEN1
SCHEMBL4976500 0.86 P2RX7 (0.42) KDM2BLMNASMN1; SMN2MEN1KMT2A
SCHEMBL4976149 0.84 HPGD (0.46) ALDH1A1LMNAHPGDMEN1KMT2A
SCHEMBL4978694 0.83 KDM2B (0.52) KDM2BALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL4978542 0.83 KDM4E (0.47) ALDH1A1LMNAMEN1KMT2AL3MBTL1
SCHEMBL4978458 0.83 KDM2B (0.52) KDM2BALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL4976255 0.83 KCNK3 (0.44) KDM2BALDH1A1LMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES HRH3, HRH4, HRH2 KDM2B 1937/4885ALDH1A1 1142/4885LMNA 4534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.